JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target?

about

Primary thrombocytosis in children.HDACi: molecular mechanisms and therapeutic implications in the innate immune system.

P2860

Q37676262-6422EAD5-F9E6-4BFE-990E-C61F31B8DC69 Q37956176-54D5454B-7633-4A9B-8171-FA429D9E5151

P2860

JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target?

Item

http://www.wikidata.org/entity/Q43246867

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

JAK Inhibitors and other Novel ...... ms: Are We Hitting the Target?

@en

JAK Inhibitors and other Novel ...... ms: Are We Hitting the Target?

@nl

type

Item

label

JAK Inhibitors and other Novel ...... ms: Are We Hitting the Target?

@en

JAK Inhibitors and other Novel ...... ms: Are We Hitting the Target?

@nl

prefLabel

JAK Inhibitors and other Novel ...... ms: Are We Hitting the Target?

@en

JAK Inhibitors and other Novel ...... ms: Are We Hitting the Target?

@nl

P1476

JAK Inhibitors and other Novel ...... ms: Are We Hitting the Target?

@en

P2093

Nicole Kucine

http://www.w3.org/2001/XMLSchema#string

Ross L Levine

http://www.w3.org/2001/XMLSchema#string

P2860

The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

P304

203-211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040620711410095

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236106947

http://www.w3.org/2001/XMLSchema#string

P698

23556090

http://www.w3.org/2001/XMLSchema#string

P932

3573410

http://www.w3.org/2001/XMLSchema#string

JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target?

about

P2860

P2860

JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932